



THE GAP IN ACCESS TO THERAPIES IN V4 IS HIGH – IT'S TIME TO ACT

Severe restrictions in access to Parkinson's disease treatment and diagnosis have been identified in the Visegrád (V4) countries as measured in the GAP score. Results vary moderately from country to country and the difference between the highest and the lowest scoring country is about 11 points. The main reason for the highly unfavourable assessment is extremely limited access to the newest registered drugs due to the lack of reimbursement, which results in 0% share of patients treated with the newest Parkinson's disease molecules or formulations.

POPULATION BURDEN

DALY* - RATE PER 100K




*disability adjusted life-years



TARGET POPULATION

PARKINSON'S DISEASE PREVALENCE




DRUG ACCESS


NUMBER OF PATIENTS TREATED (2021)



POPULATION TREATED (%)




CROSS-COUNTRY



HUGE GAP | MEDIUM GAP | LOW GAP



FROM REGISTRATION TO REIMBURSEMENT



LEGEND

Authorization date



Date of regular reimbursement

1162 Number of days



MAIN ISSUES

- The average time to reimbursement for Parkinson's disease drugs in the V4 countries is almost 6.3 years. The difference between the shortest and the longest mean time to reimbursement among the countries is below 0.5 year.
- The three most recently authorised drugs in Parkinson's disease were not reimbursed in V4 states in 2021 both in regular reimbursement and early access program. The proportion of patients in the target group treated with these drugs is then 0% in all V4 countries.
- Population burden in V4 states is much lower than the European Union average. An strongly increasing trend of DALY values was observed in V4 states in past years.



COMPLIANCE WITH GUIDELINES

All the 3 most recently authorised drugs in Parkinson's disease fall into the groups of drugs recommended by clinical guidelines. Nevertheless those drugs are generally not reimbursed in V4 region: one drug is covered with reimbursement in Czechia and one in Hungary only.



G.A.P. PROJECT

We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).

FIND OUT MORE AT GAPV4.EU

